Potential of serum soluble CD93 as a biomarker for asthma in an ovalbumin-induced asthma murine model

Abstract

Background: CD93 is a membrane-associated glycoprotein, which can be released in a soluble form (sCD93) into the serum. CD93 has received renewed attention as a candidate biomarker of inflammation in various inflammatory and immune-mediated diseases, including asthma.

Objective: We aimed to evaluate the effects of airway inflammation on CD93 levels in murine models.

Methods: We established an ovalbumin (OVA)-induced acute asthma murine model (OVA model) and a lipopolysaccharide (LPS)-induced airway inflammation murine model (LPS model). Dexamethasone was administered by gavage to attenuate the airway inflammation.

Results: The OVA model demonstrated typical allergic asthma features with increased airway hyper-responsiveness, inflammatory cell infiltration, increased Th2 cytokine levels, compared to the control group. CD93 levels were decreased in lung homogenates and, respiratory epithelial cells, whereas serum sCD93 levels were increased in the OVA model, as compared to the control group. Dexamethasone reversed these effects of OVA. In contrast, in the LPS model, CD93 levels were not affected in neither respiratory epithelial cells nor serum.

Conclusions: Our findings demonstrate the potential of using sCD93 as a biomarker for allergic asthma.

Keywords:

• Airway
• asthma
• biomarker
• CD93
• inflammation
• ovalbumin

Disclosure statement

The authors report no conflicts of interest

Additional information

Funding

This work was supported by the National Research Foundation of Korea (NRF) grant, funded by the Korean government (Ministry of Science, ICT and Future Planning), under grant No. 2015R1C1A1A02036533.